Novavax will supply 1,100 million vaccines to COVAX

The biotech company Novavax has agreed to supply 1.1 billion doses of its experimental COVID-19 vaccine for use in more than 190 low- and middle-income countries.

The company reported Thursday that it reached an agreement with the Global Alliance for Vaccines and Immunization (GAVI) to provide vaccines to the COVAX mechanism, a project spearheaded by GAVI, the World Health Organization and the Coalition for Innovations in Preparedness for Epidemics

They are working with groups that include UNICEF, the World Bank and charities to ensure that all countries have equal access to coronavirus vaccines.

Novavax Inc., based in Gaithersburg, and the Serum Institute of India, one of the leading manufacturers of vaccines for poor countries, will develop and distribute the Novavax vaccine. It is still in two advanced phase studies, one in the United States and Mexico, and the other in Britain.

Novavax said testing found the vaccine to work against the parent strain of COVID-19 and against variants first identified in Britain and South Africa, which are already widely circulating.

The company is expected to supply doses mainly to rich countries. The Serum Institute will provide most of the vaccines for poor and middle-income countries, under a tiered pricing agreement.